Delivery Order SPE2DB22D3301-SPE2DB25FY4UP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 mL vials with a ceiling value of $1,501.90. This non-competitive, firm fixed-price delivery order was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Gadavist is a contrast agent used in medical imaging procedures, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $2,961.64 to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 ml vials. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by July 21, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitively awarded delivery order valued at $9,097.83 for Gadavist 10 mmol/10 ml vials from the Defense Logistics Agency's Medical Supply Chain on September 19, 2025, with a completion date of September 22, 2025. This firm fixed-price delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,175.30 to AmerisourceBergen Drug Corp for the supply of Gadavist 1 mmol/ml bulk vials (30ml). This competitively awarded, firm fixed-price delivery order was issued on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a small-value...
- The Defense Logistics Agency awarded a $3,612.16 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gadavist 7.5 mmol/7.5 ml vials. The contract, classified as firm fixed price with no set-aside designation, is scheduled for completion by September 15, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a pediatric or diagnostic imaging pharmaceutical product supporting federal medical...
- This is a $2,366.62 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the pharmaceutical product Gadavist, a 10 milliliter vial containing 10 millimoles per milliliter. The delivery order has a completion date of June 11, 2025 and is not set aside for any small business categories. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,978.68 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4562056165 Gadavist 1 mmol/ml bulk vials. Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, will deliver 30 ml vials of Gadavist, a gadolinium-based contrast agent, to a location in Conshohocken, Pennsylvania by September 6, 2023 to support the Defense Logistics Agency's medical supply needs. No subcontractors or set aside designations were...
- This is a $1,704.90 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of Gadavist 1 mmol/ml bulk vials, a pharmaceutical product. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a $1,040.96 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is to supply the drug Gadavist, a contrast agent used in medical imaging procedures. The delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Gadavist 10 mmol/10 ml vial (10 ml). The order has a ceiling value of $16,681.09 and is a firm fixed-price contract. The period of performance runs through September 9, 2024. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued at up to $999,999,999 and $750,000, respectively,...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY4UPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,704.90 to AmerisourceBergen Drug Corp for Gadavist 1 mmol/ml bulk vials (30 ml) on May 14, 2025, with an ultimate completion date of May 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Gadavist is a gadolinium-based contrast agent used in magnetic resonance imaging procedures within military and federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle valued through December 2026. As a major pharmaceutical distributor serving the Defense Health Agency and other federal healthcare systems, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's consistent receipt of competitively awarded delivery orders demonstrates its established capability to meet federal medical procurement requirements through the DLA's Medical Supply Chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 5/14/25 |